CureVac N.V. (NASDAQ:CVAC) Q4 2022 Earnings Conference Call April 25, 2023 9:00 AM ET

Company Participants

Alexander Zehnder - CEO

Pierre Kemula - CFO

Myriam Mendila - Chief Development Officer

Sarah Fakih - VP Corporate Communications and IR

Conference Call Participants

Jonathan Miller - Evercore ISI

Ellie Merle - UBS

Eun Yang - Jefferies

Roy Buchanan - JMP Securities

Evan Wang - Guggenheim Partners

Andy Chen - Berenberg

Luisa Morgado - Kempen

Charlie Yang - Bank of America

Operator

Greetings, and welcome to the CureVac Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Sarah Fakih, Vice President Corporate Communications and Investor Relations. Thank you. You may begin.

Sarah Fakih

Thank you. Good morning, good afternoon and welcome to our conference call. My name is Sarah Fakih, and I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers.

On the call with me from CureVac are Alexander Zehnder, Chief Executive Officer of CureVac; Myriam Mendila, our Chief Development Officer; and Pierre Kemula, Chief Financial Officer of CureVac. Please note that this call is being webcast live and will be archived on the Events & Presentations section under Investor Relations on our Web site.

Before we begin, a few forward-looking statements. The discussions and responses to your questions on this call reflect management's view as of today, Tuesday, April 25, 2023. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations or predictions of the future. These constitute forward-looking statements for the purpose of the Safe Harbor provisions. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. CureVac disclaims any intention or obligation to revise any forward-looking statements. For more information, please refer to our filings with the U.S. Securities and Exchange Commission.

I will now turn the call over to Alexander.

Alexander Zehnder

Thank you, Sarah. Ladies and gentlemen, good morning, good afternoon to everybody on the webcast. On April 1 this year, I took over the leadership of CureVac that pioneer in mRNA technology and a company that is at an inflection point, transforming from a research oriented biotech to a fully integrated commercial biopharma company.